DESCRIPTION

Vascular Pharmacology is a journal of Vascular Biology and Medicine. We seek to rapidly publish transformative papers, reviews, and perspectives on vascular cells across the disciplines of biochemistry, pharmacology, pathology, physiology, molecular and developmental biology, and clinical medicine using sophisticated tools in genomics/proteomics/transcriptomics, genetics, genome editing, and bioengineering.

The journal will consider submissions that address vascular cells in the context of: Atherosclerosis, thrombosis, hemostasis Neurovascular diseases Diabetes, obesity, and metabolic syndrome Pulmonary hypertension Cardiovascular toxicity induced by anticancer drugs Transplant arteriopathy Vascular aging, repair, and regeneration Reperfusion injury Immunological influence in vascular diseases Microvascular dysfunction

AUDIENCE

Researchers in vascular biology and pharmacology, vascular disease modeling, clinical studies in vascular medicine, molecular genetics and genomics, and cell signaling.

IMPACT FACTOR

2022: 4.000 © Clarivate Analytics Journal Citation Reports 2023

ABSTRACTING AND INDEXING

Embase
PubMed/Medline
Scopus

EDITORIAL BOARD

Editor-in-Chief
Joseph Miano, Augusta University, Augusta, Georgia, United States of America
CRISPR editing in mice, gene regulation in mice, long noncoding RNAs, Molecular Biology
Senior Associate Editor
Rosalinda Madonna, University of Pisa, Pisa, Italy
Atherosclerosis, Cell therapy, Pulmonary hypertension

Consulting Editors
David Fulton, Augusta University, Augusta, Georgia, United States of America
angiogenesis, endothelium, nitric oxide synthase, obesity, pulmonary hypertension, Reactive Oxygen Species (ROS), vascular permeability, vascular smooth muscle
Peter Libby, Harvard Medical School, Boston, Massachusetts, United States of America
Lipids, Metabolism, Endocrine, Vascular, Cardiovascular Medicine
Dianna Milewicz, The University of Texas System, Houston, Texas, United States of America
Ryozo Nagai, The University of Tokyo, Bunkyo-Ku, Japan
Eric Olson, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

Associate Editors
Andrew H. Baker, The University of Edinburgh, Edinburgh, United Kingdom
Vascular biology
Gerard Pasterkamp, Utrecht University, Utrecht, Netherlands
Cang-Bao Xu, Xi'an Medical University, Xian, China
Pharmacology, Vascular biology, Translational medicine

Editorial Board
Qing Lyu, Chinese Academy of Sciences Chongqing Institute of Green and Intelligent Technology, Chongqing, China
Vascular biology, RNA biology, Genome editing
Sebastian Albinsson, Lund University, Lund, Sweden
Vascular Physiology
Andrea Caporali, The University of Edinburgh, Edinburgh, United Kingdom
Cardiology, pulmonary hypertension, heart failure
Cecilia Becattini, University of Perugia, Perugia, Italy
Cardiovascular Consequences of obesity and HIV in males and females - obesity - HIV - viral proteins - sex differences - leptin - endothelial function - vascular reactivity - oxidative stress
Eduardo Bossone, Antonio Cardarelli Hospital, Cardiology Division, Napoli, Italy
Pharmacology, Signal Transduction, Protein Phosphorylation, Chemical Biology, Metabolism
Giuseppe Cirino, University of Naples Federico II, Napoli, Italy
Blood Immune system Vascular inflammation, in vivo animal models and in vitro isolated tissue and cell models cardiovascular in vivo and in vitro cell and isolated tissue models Bioassay for mediators, immunoassay and RIA ex vivo evaluation of mediators and cellular signals for methods at point 1 and 2
Ilze Bot, Leiden University, Leiden, Netherlands
Cardiovascular diseases, Atherosclerosis, Inflammation, Mast cell, immunology, pharmacology, biologicals
Ralf Brandes, Goethe University Frankfurt, Frankfurt am Main, Germany
Mairi Brittan, The University of Edinburgh, Edinburgh, United Kingdom
Giovanni Camici, University of Zurich, Zurich, Switzerland
Vascular biology
Hong Chen, Boston Children's Hospital, Boston, Massachusetts, United States of America
Yabing Chen, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Calcium, vascular biology, calcification, atherosclerosis, death domain, vascular, smooth muscle, drug resistance, oxidative stress, Akt PKB, cardiovascular disease, vascular smooth muscle cells
William Chilian, Northeast Ohio Medical University, Rootstown, Ohio, United States of America
Coronary Physiology, Coronary Microcirculation, Angiogenesis, Collateral Growth, Mitochondrial Function
Gianluigi Condorelli, Humanitas University, Milano, Italy
Vascular calcification
Linda Demer, University of California Los Angeles, Los Angeles, California, United States of America
Francesco Cosentino, Karolinska Institute, Stockholm, Sweden
Jozef Dulak, Jagiellonian Institute in Kraków, Krakow, Poland
Leonardo Elia, University of Brescia, Brescia, Italy
Costanza Emanuelli, University of Bristol, Bristol, United Kingdom
Gabrielle Fredman, Albany Medical College, Albany, New York, United States of America
Vascular Dementia, Aortic Stiffness, ERK signaling, Myometrial signaling

Kiran Musunuru, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Cardiovascular genetics, Genome editing

Rama Natarajan, City of Hope Beckman Research Institute, Duarte, California, United States of America

Jan Nilsson, Lund University, Lund, Sweden
Atherosclerosis, immunity, biomarkers

Koichi Node, Saga University, Saga, Japan

Stylianos Orfanos, National and Kapodistrian University of Athens School of Health Sciences, Athens, Greece

Hongyu Qiu, The University of Arizona, Tucson, Arizona, United States of America
Cardiovascular physiology and molecular biology

Marlene Rabinovitch, Stanford University, Stanford, California, United States of America

Jun Ren, Zhongshan Hospital Fudan University, Shanghai, China
Metabolic disease, Heart failure, Cardiomyopathy

Daisy Sahoo, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
Scavenger receptors, lipoproteins, atherosclerosis, protein structure/function

Luis Fernando Santana, UC Davis Health, Sacramento, California, United States of America

Ann Marie Schmidt, NYU Langone Health, New York, New York, United States of America

Sruti Shiva, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
Cardiovascular

Sanjay Sinha, University of Cambridge, Cambridge, United Kingdom

Judith Sluimer, Maastricht University, Maastricht, Netherlands

Eric M. Small, University of Rochester Medical Center, Rochester, New York, United States of America
Fibrosis, Fibroblasts, mouse genetics, coronary vessels, developmental biology

Avrim Somlyo, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America
Physiology, smooth muscle, signaling, contractile proteins

David Stepp, Augusta University, Augusta, Georgia, United States of America

Patrik Turowski, University College London, London, United Kingdom
Blood brain barrier, Neurovascular Unit, Cell signalling, Paracellular junctions, Caveolae, Vascular permeability, Neurodegeneration, Diabetic microvascular disease

Masuko Ushio-Fukai, Augusta University, Augusta, Georgia, United States of America

Gemma Vilahur, Institute for Research in Biomedicine, Barcelona, Spain

Hong Wang, Temple University, Philadelphia, Pennsylvania, United States of America

Rong Wang, University of California San Francisco, San Francisco, California, United States of America
Vascular Biology

Mary Weiser Evans, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America
Vascular Biology, Vascular Stem Cells, Pathological Vascular Remodeling, Atherosclerosis

Paul Witting, The University of Sydney, Sydney, New South Wales, Australia
nitric oxide biology, inflammamtry disease, antioxidants, redox biology

Beata Wojciak-Stothard, Imperial College London, London, United Kingdom
vascular, endothelium, pulmonary hypertension, organ-on-a-chip, signalling

Yong J. Xu, Nanjing Medical University, Nanjing, China
transcription, epigenetics, hepatology, cardiology, vascular biology, pharmacology

Chen Yan, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America

Vascular Biology, Molecular Pathology, Experimental Animal Study, Elastic fibers, Skin dermal ECM, Extracellular matrix, Mechanobiology

Yuyu Yang, Nanjing Normal University, Nanjing, China
cardiovascular disease, vascular smooth muscle, epigenetic, histone modifications, transcription

Jiliang Zhou, Augusta University, Augusta, Georgia, United States of America

Aijun Sun, Zhongshan Hospital Fudan University, Shanghai, China
cardiac protection energy metabolism

Zhiyong Lin, Emory University School of Medicine, Atlanta, Georgia, United States of America
Vascular biology, Endothelial function, Aortic aneurysm and dissection, Extracellular matrix, Cardiovascular signaling, Atherosclerosis

Jing Wang, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
the pathological mechanism, molecular diagnosis and treatment of cardiopulmonary vascular and related diseases.

Sabine Steffens, LMU Munich, München, Germany
Vascular Biology, vascular and cardiac disease, inflammation, endocannabinoid system

Bina Joe, The University of Toledo - Health Science Campus, Toledo, Ohio, United States of America
Microbiota, Epigenetics, Omics Data, Genetics, Metabolites, Hypertension, Antibiotics, anti-hypertensive medications

AUTHOR INFORMATION PACK 22 Oct 2023 www.elsevier.com/locate/vph
Patrick Pagano, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Mohamed Trebak, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America


Ljubica Matic, Karolinska Institute, Stockholm, Sweden

Carmine Dario Vizza, University of Rome La Sapienza, Roma, Italy

Kathleen Martin, Yale School of Medicine, New Haven, Connecticut, United States of America

Vascular smooth muscle phenotypic modulation, Mouse models, Intimal hyperplasia, Atherosclerosis, Transplant/allograft vasculopathy, Mouse models, Epigenetics, Transcription, Signal transduction, mTOR/rapamycin analogs, Prostacyclin, Adiponectin

Vincenzo Lionetti, Sant'Anna School of Advanced Studies, Pisa, Italy

cardiovascular protection, heart-brain axis, heart failure, epigenetics, small and large animal models

Lucio Barile, Cardiocentro Institute, Lugano, Switzerland

Cellular Biology; Extracellular Vesicles; Cardiovascular Diseases

Marika Massaro, Institute of Clinical Physiology National Research Council, Pisa, Italy

Statistical Editor

Santu Ghosh, Augusta University, Augusta, Georgia, United States of America

High-dimensional data analysis, Bootstrap, Non-inferiority clinical trials, Model selection

Managing Editor

Susan Ware, Jacksonville, OR, United States of America

Immunopathology

Former Editors-in-Chief

John D. Catravas, Norfolk, Virginia, United States of America

Raffaele De Caterina, Pisa, Italy

Cardiology, Cardiovascular Pharmacology, antithrombotic drugs, Atrial fibrillation, Coronary artery disease

Clinton Webb, Columbia, South Carolina, United States of America
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.

INTRODUCTION
Vascular Pharmacology publishes manuscripts, written in English, which contain results encompassing all aspects of vascular biology and vascular medicine.

Areas of interest include angiogenesis, atherosclerosis, blood element-vessel wall interactions, cell signaling, epigenetics, gene/genome editing, hypertension, 'omics studies including proteomics, metabolomics, single cell and spatial transcriptomics, thrombosis, vascular development, vascular inflammation and immunity, vascular remodeling, and vasoactive mediators. We are particularly interested in research utilizing approaches ranging from molecular biology, genetics, and next generation sequencing to animal models and integrative physiology.

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all Authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher.

It is essential to give a fax number and institutional e-mail address when submitting a manuscript. We no longer accept personal (eg, @gmail, @163, @126) e-mail addresses. Manuscripts without an institutional email will be promptly returned to the corresponding author.

For more details on how to write a world class paper, please visit our Pharmacology Author Resources page.

Authors are encouraged to submit video material or animation sequences to support and enhance your scientific research. For more information please see the paragraph on video data below.

Fast processing option
If your article has previously been rejected from another journal, the Editors can process your submission to Vascular Pharmacology more quickly if the previously received reviewer's comments are made available to them. Please note that these will have to be sent (by email) by the Editor(s) of the respective other journal, we do not accept reviewer's comments submitted from the authors themselves. For questions please contact Journal Article Publishing Support Hub

Types of paper
Research articles

Original research articles present data that advance the science and clinical practice of vascular pathobiology, medicine, or pharmacology. Manuscripts should present rigorous, well-controlled studies reporting innovative advances that further knowledge about a topic of importance to the specialty of vascular biology, medicine, or pharmacology. Each manuscript should contain an abstract with clearly stated objective or hypothesis, primary results, and conclusion; an introduction that describes previous results and the gap in knowledge to be addressed; experimental design and methods, including proper institutional assurances for animal and clinical studies; the results of the study; and a scholarly discussion placing the results in context with the published literature as well as study limitations and overall conclusion with historical and up-to-date references.

The text of research article should be limited to 5000 words including title, abstract, tables, figures, and references list with not more than 5 figures and tables and 40 references.

Please upload your manuscript via Editorial Manager choosing manuscript type “research article”.

AUTHOR INFORMATION PACK 22 Oct 2023 www.elsevier.com/locate/vph
Reviews

Reviews should provide a balanced synthesis of prior knowledge and new scholarly advances in vascular biology, medicine, or pharmacology. They should be comprehensive, but not a reiteration of details found in previous reviews. Perspectives are shorter than reviews and should provide a summary of new and emerging themes in vascular biology, medicine or pharmacology. Reviews and Perspectives cover aspects of a topic in which scientific consensus exists as well as aspects that remain controversial and are the subject of ongoing scientific research. Please consult Editor-in-Chief with a brief outline related to a proposed Review or Perspective before submission.

Reviews shall have a maximum length of 6,000 words (the word count limit includes title, abstract, tables, figures, and references list). They should have an abstract of not more than 200 words, not more than 80 references and up to 8 figures/tables.

Please upload your manuscript via Editorial Manager choosing manuscript type “Review”.

Editorials

Editorials provide a forum for opinionated discussions of a topic in the field of vascular pharmacology, or describing historical foundations and influences, emerging research trends and clinical issues.

Editorials should be approximately 1000–2000 words and contain no more than 10–15 references. Please upload your manuscript via Editorial Manager, choosing manuscript type “Editorial” Please make a note in the title page if the editorial is a tie-in to another manuscript. For tie-in editorials, cite the original article to which it is referring in your references.

The journal will not consider unsolicited editorials or short commentaries. These are best handled in the context of a perspective or review

Research Letters to the Editor

Research Letters may present original unpublished studies of a more preliminary nature, or a discussion of patient cases.

Research Letters should be no longer than 1000 words, with no more than 1 figure and 1 table (or 2 tables and no figures or 2 figures and no tables), and a maximum of 10 references. Research letters should not include abstracts, and the number of authors should not exceed ten.

Please upload your manuscript via Editorial Manager choosing manuscript type “Letter-to-the-Editor”.

Short Communications

Short Communications are short papers that present original and significant material for rapid dissemination. For example, a Short Communication may focus on a particular aspect or a new finding that is expected to have a significant impact. Short articles include, but are not limited to: discovery or development of new materials, cutting-edge experiments and theory, novelty in simulation and modeling, elucidation of mechanisms. As Short Communications are expected to have higher than average impact on the field rather than report on incremental research, they will receive prioritized and rapid publication.

Short Communications are limited to 3000 words and are not subdivided. The paper should contain an abstract, main body and references, and contain no more than 6 figures or tables, combined. The abstract is limited to 100 words.

Please upload your Letter to the Editor via Editorial Manager choosing manuscript type “short communication”.

Commentary and Replies
Commentary about an article published in the journal is allowed. The text should raise a question for clarification, offer an alternative perspective, or explain a flaw in methodology or a perceived misinterpretation of data. Commentary should not be used as an avenue to introduce new material without subjecting it to typical peer review. The authors of the paper being commented will be notified by the Editor and asked to respond to the comment concerning their paper. The commentary and the replies would be published together.

The text of commentary should be limited to 500 words and contain no figure.

Please upload your manuscript via Editorial Manager choosing manuscript type “Commentary”.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• Institutional email address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
• DOI of same work uploaded to a preprint server such as bioRxiv.
• GEO numbers for all next generation sequencing (eg, scRNA-seq, bulk RNA-seq, ChIP-seq, etc).
• Evidence of antibody authentication should be included;(eg, siRNA knockdown or genetic knockout in an animal model; preabsorption with peptide; transfected cells with gene of interest)
• labeled molecular weight markers for all Western blots;
• Rigor in Western blot reporting with at least two (and preferably three) replicates in each blot;
• All bar graphs should be in scatterplot format containing biological replicates or means of technical replicates across 3 or more independent studies;
• HUGO Gene Nomenclature Committee (HGNC) approved gene symbols must be used throughout and with correct syntax (eg, human endothelial nitric oxide synthase gene, promoter or mRNA is NOS3 and protein is NOS3; for rodents it would be Nos3 and NOS3, respectively). Please go here for more details about gene symbols.

For further information, visit our Support Center.

Cover letter
Authors should indicate in a cover letter to the Editor the following assurances:
• All authors have reviewed and approve of the contents of the manuscript and its conclusions
• The manuscript has not been submitted in part or in whole to another journal except for preprint journals such as bioRxiv. In the latter instance, a doi number should be provided
• A single author’s institutional email address is provided with current address and contact numbers

• That the data provided are original findings conducted in the lab of the corresponding author and that original data (eg, Western blots, flow cytometry) are available for eventual uploading as a supplemental file.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing and a position piece on Scientific Integrity in Publications ("https://doi.org/10.1161/atvbaha.109.200204"10.1161/ATVBAHA.109.200204

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council’s Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of competing interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using this template and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose the first option in the template. More information.

Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.
Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Preprint posting on SSRN
In support of Open Science, this journal offers its authors a free preprint posting service. Preprints provide early registration and dissemination of your research, which facilitates early citations and collaboration.

During submission to Editorial Manager, you can choose to release your manuscript publicly as a preprint on the preprint server SSRN once it enters peer-review with the journal. Your choice will have no effect on the editorial process or outcome with the journal. Please note that the corresponding author is expected to seek approval from all co-authors before agreeing to release the manuscript publicly on SSRN.

You will be notified via email when your preprint is posted online and a Digital Object Identifier (DOI) is assigned. Your preprint will remain globally available free to read whether the journal accepts or rejects your manuscript.

For more information about posting to SSRN, please consult the SSRN Terms of Use and FAQs.

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blacklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses

Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research’s generalizability. Importantly, authors should explicitly state what
definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

**Definitions**

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

**Author contributions**

For transparency, we require authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Article transfer service**

This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

**Open access**
Please visit our Open Access page for more information about open access publishing in this journal.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Referees**
Please suggest 4 potential reviewers for this submission. At least 2 of the suggested reviewers should be located in the USA or Europe.

**PREPARATION**
**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**NEW SUBMISSIONS**
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality
figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions. If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes. Divide the article into clearly defined sections.

Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Manuscripts deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the manuscript. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about manuscript which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork. To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Essential title page information
- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the institutional e-mail address is given and that contact details are kept up to date by the corresponding author.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

The abstract should have a maximum of 250 words.

Graphical abstract
A graphical abstract is encouraged for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Keywords
**Keywords.** Immediately after the abstract, provide a maximum of 5 keywords, avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Nomenclature and units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUPAC: Nomenclature of Organic Chemistry for further information.

Please ensure Human Genome Nomenclature Committee (see https://www.genenames.org/) standards are followed for gene and protein symbols. Human genes/RNA/promoter symbols are italicized and upper case (eg, MYOCD); rodent genes/RNA/promoter are italicized lower case (eg, Myocd). Protein symbols for all mammalian species are non-italicized and upper case (eg, MYOCD). Please refrain from aliases and use the official gene/protein symbol in all text and figures.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Text graphics

Text graphics may be embedded in the text at the appropriate position. If you are working with LaTeX and have such features embedded in the text, these can be left. See further under Electronic artwork.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Reference to software:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal requires and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. When sharing data in one of these ways, you are expected to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.
For **supported data repositories** a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Research Elements**
This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the Research Elements page.

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com